Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nefazodone in social phobia.

M Van Ameringen1, C Mancini, J M Oakman

  • 1Anxiety Disorders Programme, Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada. vanamer@fhs.mcmaster.ca

The Journal of Clinical Psychiatry
|March 20, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obsessive-compulsive disorder during the COVID-19 pandemic.

Journal of psychiatric research·2022
Same author

How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology.

Comprehensive psychiatry·2020
Same author

The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study.

Acta psychiatrica Scandinavica·2020
Same author

Manifesto for a European research network into Problematic Usage of the Internet.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2018
Same author

HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Prevalence and phenotype of the c.1529C>T SPG7 variant in adult-onset cerebellar ataxia in Italy.

European journal of neurology·2018
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Nefazodone, a novel serotonergic drug, showed efficacy in treating social phobia. This 12-week open trial found significant improvements in social anxiety, avoidance, depression, and functioning for most participants.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Social phobia, a common anxiety disorder, necessitates effective pharmacologic treatments.
  • Nefazodone, a novel serotonergic agent, was investigated for its therapeutic potential in social phobia.

Observation:

  • A 12-week open-label trial involved 23 patients diagnosed with generalized social phobia.
  • Nefazodone dosage was titrated based on clinical response and tolerability.
  • Multiple validated self-report and clinician-rated scales assessed social anxiety, depression, and functioning.

Findings:

  • Twenty-one patients completed the trial, with 69.6% demonstrating moderate to marked improvement.
  • Statistically significant reductions were observed in social anxiety, avoidance behaviors, and depressive symptoms.

Related Experiment Videos

  • Improvements in overall social functioning were also noted at the study's conclusion.

    • Implications:

    • Nefazodone shows promise as a treatment option for generalized social phobia.
    • Further controlled studies are warranted to confirm efficacy and compare with existing treatments.
    • This research contributes to understanding novel pharmacologic interventions for social anxiety disorders.